ARDX Ardelyx
- 6.7900
- +0.1800+2.72%
- 7.6500
- +0.8600+12.67%
Ardelyx News
Express News | Ardelyx Inc Shares up 10% at $7.48 After the Bell Following Results
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersTwist Bioscience (NASDAQ:TWST) stock increased by 14.1% to $36.51 during Thursday's after-market session. The company's market cap stands at $2.1 billion. The company's, Q2 earnings came out to
Express News | Ardelyx Inc - Qtrly Shr Loss $0.11
Earnings Flash (ARDX) ARDELYX Reports Q1 Revenue $46M, Vs. Street Est of $36.4M
04:10 PM EDT, 05/02/2024 (MT Newswires) -- Earnings Flash (ARDX) ARDELYX Reports Q1 Revenue $46M, vs. Street Est of $36.4M
Ardelyx Q1 2024 GAAP EPS $(0.11) Beats $(0.15) Estimate, Sales $46.023M Beat $36.397M Estimate
Ardelyx (NASDAQ:ARDX) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.15) by 26.67 percent. This is a 15.38 percent increase over losses of $(0.13) per
Express News | Ardelyx Q1 Operating Expenses USD 63.573 Million
Express News | Ardelyx Q1 Product Sales USD 43.512 Million
Express News | Ardelyx Q1 Net Income USD -26.518 Million
Express News | Ardelyx Reports First Quarter 2024 Financial Results and Provides Business Update
Express News | Ardelyx Q1 Operating Income USD -24.678 Million
Ardelyx 1Q Loss/Shr 11c >ARDX
Ardelyx 1Q Loss/Shr 11c >ARDX
Ardelyx(ARDX.US) Officer Sells US$192.06K in Common Stock
$Ardelyx(ARDX.US)$ Officer RAAB MICHAEL sold 30,000 shares of common stock on Apr 29, 2024 at an average price of $6.4019 for a total value of $192.06K.Source: Announcement What is statement of change
Express News | Ardelyx To Present Additional Data For XPHOZAH For Adults With Chronic Kidney Disease On Dialysis At National Kidney Foundation 2024 Spring Clinical Meetings
Ardelyx to Present Additional Data Supporting First-In-Class XPHOZAH (Tenapanor) for Adults With Chronic Kidney Disease on Dialysis at the National Kidney Foundation 2024 Spring Clinical Meetings
WALTHAM, Mass., May 01, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class me
Form 144 | Ardelyx(ARDX.US) Officer Proposes to Sell 192.05K in Common Stocks
SEC FILLINGS DISCLOSED/ Apr 29, $Ardelyx(ARDX.US)$ Officer MICHAEL G. RAAB intends to sell 30,000 shares of its common stock on Apr 29, with a total market value of approximately $192.05K. MICHAEL G
Ardelyx's (NASDAQ:ARDX) Investors Will Be Pleased With Their Favorable 91% Return Over the Last Five Years
Piper Sandler Sticks to Its Buy Rating for Ardelyx (ARDX)
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024
Conference call scheduled for 4:30 p.m. Eastern TimeWALTHAM, Mass., April 18, 2024 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, d
Ardelyx(ARDX.US) Officer Sells US$52,923.75 in Common Stock
$Ardelyx(ARDX.US)$ Officer RAAB MICHAEL sold 7,500 shares of common stock on Apr 15, 2024 at an average price of $7.0565 for a total value of $52,923.75.Source: Announcement What is statement of chang
Ardelyx Is Maintained at Outperform by Wedbush
Ardelyx Is Maintained at Outperform by Wedbush
Analysis
Price Target
No Data
